Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy.

Abstract:

INTRODUCTION:Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS:This is a retrospective study including patients who presented with lung oligometastasis from CRC treated with SABR from September 2007 to November 2014. RESULTS:We identified 53 oligometastatic patients with 87 lung lesions. The median prescription dose was 60 Gy in 3 fractions (median biological effective dose of 180 Gy). The median follow up was 33 months. The 1- and 2-year local control, metastasis-free survival, and overall survival were 79.8% and 78.2%, 29.2% and 16.2%, and 83.8% and 69.3%, respectively. On multivariate analysis, rectal primary site (P = .001) and > 2 metastases (P = .02) were significantly associated with a lower local control rate. Rectal lesions were associated with higher radiation dose (169.3 Gy vs. 153.3 Gy; P = .01) and higher rate of KRAS mutations (73.3% vs. 40.4%; P = .02). KRAS mutation did not predict for local control, but predicted for a 1-year metastasis-free survival detriment (0% vs. 37.5%; P = .04), when compared with KRAS wild-type. On multivariate analysis, there is an overall survival detriment associated with gross tumor volume ≥ 3266 mm3 (P = .03) and > 2 metastases (P = .04). CONCLUSION:In CRC, oligometastatic lung lesions treated with SABR had a worse outcome in patients presenting with a rectal primary, > 2 metastases, or treated with a larger gross tumor volume. More aggressive treatment may be considered in this subset of patients to improve outcome.

journal_name

Clin Colorectal Cancer

authors

Kinj R,Bondiau PY,François E,Gérard JP,Naghavi AO,Leysalle A,Chamorey E,Evesque L,Padovani B,Ianessi A,Benezery K,Doyen J

doi

10.1016/j.clcc.2016.08.003

subject

Has Abstract

pub_date

2017-09-01 00:00:00

pages

e211-e220

issue

3

eissn

1533-0028

issn

1938-0674

pii

S1533-0028(16)30150-5

journal_volume

16

pub_type

杂志文章
  • Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.

    abstract:BACKGROUND:In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2006.n.037

    authors: Wolpin BM,Clark JW,Meyerhardt JA,Earle CC,Ryan DP,Enzinger PC,Zhu AX,Blaszkowsky L,Battu S,Fuchs CS

    更新日期:2006-09-01 00:00:00

  • Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.

    abstract::Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2001.n.006

    authors: Copur S,Ledakis P,Novinski D,Mleczko KL,Frankforter S,Bolton M,Fruehling RM,VanWie E,Norvell M,Muhvic J

    更新日期:2001-05-01 00:00:00

  • Locoregional strategies for colorectal hepatic metastases.

    abstract::Hepatic colorectal metastases present a challenging problem in patients with recurrent colorectal cancer. Twenty percent of patients with recurrence will have liver metastases as a component of their disease, and only 10% of these patients will have isolated liver metastases that are resectable. Although systemic chem...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2003.n.010

    authors: Meyers MO,Sasson AR,Sigurdson ER

    更新日期:2003-05-01 00:00:00

  • Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor.

    abstract::Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2009.n.025

    authors: Bhattacharya A,Tóth K,Sen A,Seshadri M,Cao S,Durrani FA,Faber E,Repasky EA,Rustum YM

    更新日期:2009-07-01 00:00:00

  • Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.

    abstract::Significant advances have been made with respect to our understanding of the critical role of agents targeting angiogenic pathways in the treatment of metastatic colorectal cancer (mCRC). The approval of 3 agents that target angiogenic signaling, bevacizumab, ziv-aflibercept, and regorafenib, provides strong evidence ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2014.02.001

    authors: Lee JJ,Chu E

    更新日期:2014-09-01 00:00:00

  • The Role of the Gut Microbiome in Colorectal Cancer: Where Are We? Where Are We Going?

    abstract::Microbiome (microbiota) is a community of all microorganisms inhabiting a specific site of the body, including pathogens, which distinguishes it from the physiological microflora. Intestinal dysbiosis plays a key role in the development of colorectal cancer. In the process of carcinogenesis, inflammation, immune respo...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2019.07.006

    authors: Wieczorska K,Stolarek M,Stec R

    更新日期:2020-03-01 00:00:00

  • Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

    abstract:BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.09.006

    authors: Siena S,Rivera F,Taieb J,Peeters M,Prenen H,Koukakis R,Demonty G,Köhne CH

    更新日期:2018-03-01 00:00:00

  • Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography.

    abstract::In the past 10 years, overall survival and disease-free survival of patients with colorectal cancer (CRC) has improved substantially because of a combination of factors: (1) more accurate staging as a result of advances in imaging technology; (2) refinements in surgical technique; (3) 'curative' metastasectomy for pat...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2009.n.013

    authors: Kapse N,Goh V

    更新日期:2009-03-01 00:00:00

  • Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

    abstract:INTRODUCTION:Bevacizumab improves outcome for patients with advanced colorectal cancer (CRC) when added to chemotherapy. The HORIZON I trial resulted in similar outcome with bevacizumab or cediranib, a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, as treatment of advanc...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clcc.2013.11.002

    authors: Bar J,Spencer S,Morgan S,Brooks L,Cunningham D,Robertson J,Jürgensmeier JM,Goss GD

    更新日期:2014-03-01 00:00:00

  • Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.

    abstract::Bevacizumab is a humanized monoclonal antibody approved by the US Food and Drug Administration for use in combination with fluorouracil (FU)-based chemotherapy for first-line treatment of patients with metastatic colorectal carcinoma (CRC). Its mechanism of action is inhibition of tumor angiogenesis by neutralizing va...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2010.n.008

    authors: Gamboa EO,Rehmus EH,Haller N

    更新日期:2010-01-01 00:00:00

  • Diverticular disease in patients with colon cancer: subgroup analysis of national surgical adjuvant breast and bowel project protocol C-06.

    abstract:BACKGROUND:Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD). The relationship between the 2 diseases is still unclear, and the impact of DD in patients diagnosed with CC on disease-free survival (DFS) and overall survival (OS) is unknown. N...

    journal_title:Clinical colorectal cancer

    pub_type: 临床试验,杂志文章

    doi:10.3816/ccc.2006.n.031

    authors: Soran A,Harlak A,Wilson JW,Nesbitt L,Lembersky BC,Wienad HS,O'Connell MJ

    更新日期:2006-07-01 00:00:00

  • Is levoleucovorin an alternative to racemic leucovorin? A literature review.

    abstract:PURPOSE:Our purpose is to perform a comprehensive literature review of the use of levoleucovorin in gastrointestinal malignancies and to assess whether levoleucovorin is a reasonable alternative to racemic leucovorin. DESIGN:This is an extensive literature review of levoleucovorin use in patients with gastrointestinal...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2009.n.034

    authors: Kovoor PA,Karim SM,Marshall JL

    更新日期:2009-10-01 00:00:00

  • Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

    abstract:BACKGROUND:New treatment modalities and a growing understanding of the complex genetic tumor landscape have improved the outcome of colorectal cancer (CRC) patients. Nonetheless, more individualized treatment regimens, taking individual tumor characteristics into account, have been recently postulated and prognostic bi...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.02.008

    authors: Semaan A,Uhl B,Branchi V,Lingohr P,Bootz F,Kristiansen G,Kalff JC,Matthaei H,Pantelis D,Dietrich D

    更新日期:2018-06-01 00:00:00

  • Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.

    abstract:BACKGROUND:The safety of bevacizumab in older mCRC patients is poorly understood. The purpose of this analysis was to determine the prevalence, incidence, and risk factors for treatment-related AEs in older bevacizumab recipients. PATIENTS AND METHODS:Patients age ≥65 were identified from SEER-Medicare and categorized...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2012.11.004

    authors: Shankaran V,Mummy D,Koepl L,Blough D,Yim YM,Yu E,Ramsey S

    更新日期:2013-09-01 00:00:00

  • Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

    abstract:BACKGROUND:No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-β receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.03.006

    authors: Hanna DL,Loupakis F,Yang D,Cremolini C,Schirripa M,Li M,Matsusaka S,Berger MD,Miyamoto Y,Zhang W,Ning Y,Antoniotti C,Salvatore L,Moran M,Zeger G,Astrow SH,Falcone A,Lenz HJ

    更新日期:2018-09-01 00:00:00

  • Real-World Effect of Maintenance and Intermittent Chemotherapy on Survival in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. PATIENTS AND METHODS:Using a populatio...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.10.011

    authors: Loree JM,Tan SK,Lafond LM,Speers CH,Kennecke HF,Cheung WY

    更新日期:2018-03-01 00:00:00

  • COVID-19 and the Global Impact on Colorectal Practice and Surgery.

    abstract:BACKGROUND:The novel severe acute respiratory syndrome coronavirus 2 virus that emerged in December 2019 causing coronavirus disease 2019 (COVID-19) has led to the sudden national reorganization of health care systems and changes in the delivery of health care globally. The purpose of our study was to use a survey to a...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.05.011

    authors: Nunoo-Mensah JW,Rizk M,Caushaj PF,Giordano P,Fortunato R,Dulskas A,Bugra D,da Costa Pereira JM,Escalante R,Koda K,Samalavicius NE,Maeda K,Chun HK,ISUCRS COVID-19 Participating Investigator Group.

    更新日期:2020-09-01 00:00:00

  • Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.08.002

    authors: Sunakawa Y,Yang D,Cao S,Zhang W,Moran M,Astrow SH,Hsiang J,Stephens C,Tsuji A,Takahashi T,Tanioka H,Negoro Y,Takagane A,Tani S,Yamaguchi T,Eto T,Fujii M,Ichikawa W,Lenz HJ

    更新日期:2018-12-01 00:00:00

  • Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer.

    abstract::Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to sel...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2010.s.006

    authors: Stein S,Cohen DJ,Hochster HS

    更新日期:2010-06-01 00:00:00

  • Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

    abstract::The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clcc.2015.05.006

    authors: Lee MS,Kopetz S

    更新日期:2015-12-01 00:00:00

  • Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System.

    abstract:BACKGROUND:Metastatic colorectal cancer (CRC) outcomes continue to improve, but they vary significantly by race and ethnicity. We hypothesize that these disparities arise from unequal access to care. MATERIALS AND METHODS:The Harris Health System (HHS) is an integrated health delivery network that provides medical car...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2019.09.002

    authors: Lau-Min K,Prakash P,Jo E,Thrift AP,Hilsenbeck S,Musher BL

    更新日期:2020-06-01 00:00:00

  • Positron emission tomography for the evaluation of patients with colorectal cancer.

    abstract::Approximately 40% of patients treated with curative intent for colorectal carcinoma eventually recur. In about one third of these patients, the lesion is localized and potentially resectable. Typically, the recurrence is characterized by findings on diagnostic imaging studies and may be accompanied by a rise in the se...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/CCC.2001.n.012

    authors: Fogarasi MC,Zelkowitz RS,Messana SA,Arrighi JA,Seibyl JP,Kummar S

    更新日期:2001-08-01 00:00:00

  • Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.

    abstract:BACKGROUND:Metastatic colorectal cancer (mCRC) is increasingly treated using targeted therapies. Their real-life evaluation is insufficient, especially in elderly and frail patients. The aim was to describe use, safety, and effectiveness of targeted therapies in first-line mCRC treatment according to age. PATIENTS AND...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2018.11.005

    authors: Gouverneur A,Coutureau J,Jové J,Rouyer M,Grelaud A,Duc S,Gérard S,Smith D,Ravaud A,Droz C,Bernard MA,Lassalle R,Forrier-Réglat A,Noize P,ETNA study group and the EREBUS study group.

    更新日期:2019-03-01 00:00:00

  • The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.

    abstract:BACKGROUND:Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type (WT) KRAS tumors. Although skin toxicities are the most common adverse events associated with EGFR in...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clcc.2011.06.004

    authors: Mitchell EP,Piperdi B,Lacouture ME,Shearer H,Iannotti N,Pillai MV,Xu F,Yassine M

    更新日期:2011-12-01 00:00:00

  • First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.

    abstract:BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2020.08.003

    authors: Winer A,Denlinger CS,Vijayvergia N,Cohen SJ,Astaturov I,Dotan E,Gallant JN,Wang EW,Kunkel M,Lim B,Harvey HA,Sivik J,Korzekwa K,Ruth K,White K,Cooper HS,Ross EA,Zhou L,El-Deiry WS

    更新日期:2020-08-19 00:00:00

  • Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.

    abstract:BACKGROUND:Systemic chemotherapy increases the possibility of resection in patients with initially unresectable colorectal cancer (CRC), especially patients with hepatic metastasis. However, the predictive factors and prognosis of conversion to resection after chemotherapy in patients with various organ metastases rema...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2017.10.002

    authors: Nozawa H,Ishihara S,Kawai K,Hata K,Kiyomatsu T,Tanaka T,Nishikawa T,Otani K,Yasuda K,Sasaki K,Kaneko M,Murono K

    更新日期:2018-03-01 00:00:00

  • Targeted therapy in colorectal cancer.

    abstract::Adjuvant therapy can reduce the risk of disease recurrence in patients with stage II-IV colorectal cancer. Recently, 3 monoclonal antibodies have been shown to improve clinical outcome in this group of patients. Bevacizumab is an antiangiogenesis agent that has been shown in clinical and preclinical models to reverse ...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2007.n.004

    authors: Wadler S

    更新日期:2007-01-01 00:00:00

  • Therapeutic Evaluation of Biofeedback Therapy in the Treatment of Anterior Resection Syndrome After Sphincter-Saving Surgery for Rectal Cancer.

    abstract:BACKGROUND:Anterior resection syndrome (ARS) is common after sphincter-saving surgery for rectal cancer. It includes changes in the frequency and urgency of bowel movements and fecal incontinence. The therapeutic efficacy of biofeedback on ARS is unclear. We sought to evaluate the effectiveness of biofeedback therapy i...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.1016/j.clcc.2015.11.002

    authors: Liang Z,Ding W,Chen W,Wang Z,Du P,Cui L

    更新日期:2016-09-01 00:00:00

  • Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

    abstract:PURPOSE:The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations. Capecitabine is also at least as effective as bolus 5-FU/LV i...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章

    doi:10.3816/ccc.2005.n.021

    authors: Twelves CJ,Butts CA,Cassidy J,Conroy T,Braud Fd,Diaz-Rubio E,Tabernero JM,Schoffski P,Figer A,Brunet R,Grossmann J,Sobrero AF,Van Cutsem EJ

    更新日期:2005-07-01 00:00:00

  • Thymidylate synthase: a critical target for cancer chemotherapy.

    abstract::Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...

    journal_title:Clinical colorectal cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CCC.2002.n.003

    authors: Rose MG,Farrell MP,Schmitz JC

    更新日期:2002-02-01 00:00:00